140 related articles for article (PubMed ID: 14505892)
1. Ii-Key/MHC class II epitope hybrid peptide vaccines for HIV.
Kallinteris NL; Lu X; Wu S; Hu H; Li Y; Gulfo JV; Humphreys RE; Xu M
Vaccine; 2003 Oct; 21(27-30):4128-32. PubMed ID: 14505892
[TBL] [Abstract][Full Text] [Related]
2. Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines.
Kallinteris NL; Lu X; Blackwell CE; von Hofe E; Humphreys RE; Xu M
Expert Opin Biol Ther; 2006 Dec; 6(12):1311-21. PubMed ID: 17223739
[TBL] [Abstract][Full Text] [Related]
3. Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer.
Gillogly ME; Kallinteris NL; Xu M; Gulfo JV; Humphreys RE; Murray JL
Cancer Immunol Immunother; 2004 Jun; 53(6):490-6. PubMed ID: 14740174
[TBL] [Abstract][Full Text] [Related]
4. Enhanced CD4+ T-cell response in DR4-transgenic mice to a hybrid peptide linking the Ii-Key segment of the invariant chain to the melanoma gp100(48-58) MHC class II epitope.
Kallinteris NL; Wu S; Lu X; Humphreys RE; von Hofe E; Xu M
J Immunother; 2005; 28(4):352-8. PubMed ID: 16000953
[TBL] [Abstract][Full Text] [Related]
5. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease.
Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E
Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713
[TBL] [Abstract][Full Text] [Related]
6. Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.
Lu X; Wu S; Blackwell CE; Humphreys RE; von Hofe E; Xu M
Immunology; 2007 Feb; 120(2):207-16. PubMed ID: 17116173
[TBL] [Abstract][Full Text] [Related]
7. CD4+ T-cell activation for immunotherapy of malignancies using Ii-Key/MHC class II epitope hybrid vaccines.
Xu M; Kallinteris NL; von Hofe E
Vaccine; 2012 Apr; 30(18):2805-10. PubMed ID: 22386748
[TBL] [Abstract][Full Text] [Related]
8. Ii-Key/HPV16 E7 hybrid peptide immunotherapy for HPV16+ cancers.
Xu M; Lu X; Sposato M; Zinckgraf JW; Wu S; von Hofe E
Vaccine; 2009 Jul; 27(34):4641-7. PubMed ID: 19520206
[TBL] [Abstract][Full Text] [Related]
9. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization.
Berzofsky JA
Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961
[TBL] [Abstract][Full Text] [Related]
10. Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein.
Bozzacco L; Yu H; Dengjel J; Trumpfheller C; Zebroski HA; Zhang N; Küttner V; Ueberheide BM; Deng H; Chait BT; Steinman RM; Mojsov S; Fenyö D
PLoS One; 2012; 7(7):e41897. PubMed ID: 22860026
[TBL] [Abstract][Full Text] [Related]
11. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs.
Shirai M; Pendleton CD; Ahlers J; Takeshita T; Newman M; Berzofsky JA
J Immunol; 1994 Jan; 152(2):549-56. PubMed ID: 8283036
[TBL] [Abstract][Full Text] [Related]
12. A bioinformatics tool for epitope-based vaccine design that accounts for human ethnic diversity: application to emerging infectious diseases.
Oyarzun P; Ellis JJ; Gonzalez-Galarza FF; Jones AR; Middleton D; Boden M; Kobe B
Vaccine; 2015 Mar; 33(10):1267-73. PubMed ID: 25629524
[TBL] [Abstract][Full Text] [Related]
13. Lymphoproliferative response to synthetic V3 loop P18 peptide and HIV-1 envelope glycoprotein among individuals immunized with gp160 candidate vaccines.
Moukrim Z; Cho YY; Mbika JP; Achour A
Biomed Pharmacother; 1996; 50(10):494-9. PubMed ID: 9091063
[TBL] [Abstract][Full Text] [Related]
14. T cell reactivity to MHC class II-bound self peptides in systemic lupus erythematosus-prone MRL/lpr mice.
Suh CH; Freed JH; Cohen PL
J Immunol; 2003 Feb; 170(4):2229-35. PubMed ID: 12574397
[TBL] [Abstract][Full Text] [Related]
15. Linkage of Ii-Key segment to gp100(46-58) epitope enhances the production of epitope-specific antibodies.
Kallinteris NL; Wu S; Lu X; von Hofe E; Humphreys RE; Xu M
Vaccine; 2005 Mar; 23(17-18):2336-8. PubMed ID: 15755623
[TBL] [Abstract][Full Text] [Related]
16. Th1 epitope peptides induce protective immunity against Rickettsia rickettsii infection in C3H/HeN mice.
Wang P; Xiong X; Jiao J; Yang X; Jiang Y; Wen B; Gong W
Vaccine; 2017 Dec; 35(51):7204-7212. PubMed ID: 29032899
[TBL] [Abstract][Full Text] [Related]
17. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.
Humphreys RE; Adams S; Koldzic G; Nedelescu B; von Hofe E; Xu M
Vaccine; 2000 Jun; 18(24):2693-7. PubMed ID: 10781856
[TBL] [Abstract][Full Text] [Related]
18. MHC class II loading of high or low affinity peptides directed by Ii/peptide fusion constructs: implications for T cell activation.
Gregers TF; Fleckenstein B; Vartdal F; Roepstorff P; Bakke O; Sandlie I
Int Immunol; 2003 Nov; 15(11):1291-9. PubMed ID: 14565927
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
20. Major histocompatibility complex class II molecule-human immunodeficiency virus peptide analysis using a microarray chip.
Gaseitsiwe S; Valentini D; Ahmed R; Mahdavifar S; Magalhaes I; Zerweck J; Schutkowski M; Gautherot E; Montero F; Ehrnst A; Reilly M; Maeurer M
Clin Vaccine Immunol; 2009 Apr; 16(4):567-73. PubMed ID: 19225081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
